Product Description
Hyperinflammation or dysregulated immune responses result from an imbalance between pro-inflammatory cytokines, such as IL-6, and anti-inflammatory cytokines, like IL-10. These conditions commonly occur in hospitalised patients, especially those in intensive care units (ICUs). Elevated levels of IL-6 in the bloodstream have been strongly associated with disease progression and outcomes, including prognosis and mortality rates. IL-6's role is particularly prominent in various conditions such as Acute Respiratory Distress Syndrome (ARDS), Acute Pancreatitis, Sepsis, Acute Kidney Injury, Cytokine Release Syndrome, Burn and Trauma, Cardiac Surgery, Pneumonia, and COVID-19. (Sourced from: https://medisieve.com/pipeline)
Mechanisms of Action: IL6 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MediSieve
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Inflammation
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|